180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method of treating frozen shoulder using an il-33/TNF bispecific antibody.” The patent application is a continuation of US Patent No. 10,500,2730 and, once granted, it will be assigned patent number US-2020-0338193-A 1. 180 Life Sciences also received a notice of acceptance for its US patent, “Method of treating early stage Dupuytren’s Disease,” with the application number 16/089,234 filed September 27, 2018. Publication is expected to occur on Feb. 11, 2020. Additionally, the company received notification that the EU has granted its application number 15726740.2, filed on Aug. 29, 2016, which will be granted Dec. 9, 2020. “The issuance of these additional patent assets significantly strengthens the IP portfolio governing our lead program,” said Dr. James Woody, CEO of 180 Life Sciences. “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having these most recent patents awarded, particularly in the EU, is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe.”
To view the full press release, visit https://nnw.fm/OcJtx
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://nnw.fm/ATNF
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
